일반의약품(OTC) 시장 : 기회와 전략(-2034년)
Over The Counter (OTC) Drugs Global Market Opportunities And Strategies To 2034
상품코드 : 1753844
리서치사 : The Business Research Company
발행일 : 2025년 06월
페이지 정보 : 영문 373 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계 일반의약품(OTC) 시장은 2019년 1,259억 654만 달러로 평가되었으며, 2024년까지 CAGR 4.00% 이상 성장했습니다.

R&D 투자 증가

연구개발에 대한 투자 증가는 역사적 기간 동안 일반의약품(OTC) 시장의 성장에 기여했습니다. 연구개발(R&D)에 대한 투자 증가는 셀프케어 치료의 기술 혁신을 촉진하여 일반의약품(OTC)의 성장을 촉진할 것입니다. 이러한 투자는 보다 효과적이고 안전한 표적 제제 개발, 약물전달 방법 개선, 규제 준수 강화에 기여하고 있습니다. 또한, R&D는 브랜드 차별화를 촉진하고, 시장 경쟁력을 강화하며, 과학적 근거가 있는 첨단 OTC 제품으로 소비자를 끌어들이고 있습니다. 예를 들어, 룩셈부르크에 본부를 둔 유럽연합(EU) 통계청 유로스타트(Eurostat)에 따르면 2023년 12월 EU의 연구개발(R&D) 지출은 2022년 3,520억 유로(3,844억 2,000만 달러)로 전년도 3,310억 유로(3,614억 8,000만 달러)에서 6.34% 증가했습니다. 이는 R&D 투자 증가가 일반의약품(OTC) 시장의 성장을 견인한 것으로 분석됩니다.

목차

제1장 주요 요약

제2장 목차

제3장 표목차

제4장 그림목차

제5장 보고서 구성

제6장 시장 특징

제7장 주요 시장 동향

제8장 일반용 의약품(OTC) 성장 분석과 전략 분석 프레임워크

제9장 일반용 의약품(OTC) 시장 : 세분화

제10장 일반용 의약품(OTC) 시장 : 지역·국가별 분석

제11장 아시아태평양 시장

제12장 서유럽 시장

제13장 동유럽 시장

제14장 북미 시장

제15장 남미 시장

제16장 중동 시장

제17장 아프리카 시장

제18장 경쟁 구도와 기업 개요

제19장 기타 주요 기업과 혁신적 기업

제20장 경쟁 벤치마킹

제21장 경쟁 대시보드

제22장 주요 인수합병

제23장 일반용 의약품(OTC)의 최근 동향

제24장 기회와 전략

제25장 일반용 의약품(OTC) 시장 : 결론과 제안

제26장 부록

ksm
영문 목차

영문목차

Over-the-counter (OTC) drugs are medications available for purchase without a prescription from a healthcare professional. They are designed for self-care, allowing individuals to manage common health issues such as headaches, colds, allergies and digestive problems.

The over the counter (OTC) drugs market consists of sales by entities (organizations, sole traders and partnerships) of over the counter (OTC) drugs that are typically used when symptoms are mild to moderate and do not require a doctor's intervention. OTC drugs often serve as the first line of treatment for minor ailments and can act as substitutes for prescription medications in certain situations. They are widely used across various settings, including homes, workplaces and while traveling, providing convenient relief from everyday health concerns.

The global over the counter (OTC) drugs market was valued at $125,906.54 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 4.00%.

Increasing Investment in Research And Development

The increasing investment in research and development contributed to the growth of the over-the-counter (OTC) drugs market in the historic period. The increasing investment in research and development (R&D) drives the growth of the over-the-counter (OTC) drug by driving innovation in self-care treatments. This investment has led to the development of more effective, safer and targeted formulations, improved drug delivery methods and enhanced regulatory compliance. Additionally, R&D fosters brand differentiation and strengthens market competitiveness, attracting consumers with advanced, science-backed OTC products. For instance, in December 2023, according to Eurostat, a Luxembourg-based statistical office of the European Union, the EU's expenditure on research and development (R&D) increased to €352 billion ($384.42 billion) in 2022, marking a 6.34% rise from €331 billion ($361.48) in the previous year. Therefore, increasing investment in research and development drove the growth of the over-the-counter (OTC) drugs market.

Development of Bioequivalent Ophthalmic Solution to Provide Eye Allergy Relief

Major companies operating in the over-the-counter (OTC) drugs market are focusing on the development of bioequivalent ophthalmic solutions to provide eye allergy relief. It offers the same therapeutic benefits at a potentially more competitive price, presenting an opportunity to drive revenue growth, expand its ophthalmic portfolio and solidify its position in the OTC pharmaceutical market. For instance, in March 2025, Glenmark Pharmaceuticals Inc., a US-based pharmaceutical company, received final approval from the U.S. Food and Drug Administration (FDA) for its olopatadine hydrochloride ophthalmic solution USP, 0.2% (OTC). This product is recognized as bioequivalent to Alcon Laboratories' Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC). Distribution in the U.S. will be managed by Glenmark Therapeutics Inc., USA. With the Pataday market generating approximately $50.7 million in annual sales, this approval presents a strategic growth opportunity for Glenmark to strengthen its ophthalmic portfolio and expand its presence in the over-the-counter eye care segment.

The global over the counter (OTC) drugs markets is fairly fragmented, with large number of players operating in the market. The top 10 competitors in the market made up 14.11% of the total market in 2023.

Over The Counter (OTC) Drugs Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global over the counter (OTC) drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Where is the largest and fastest-growing market for over the counter (OTC) drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The over the counter (OTC) drugs market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider over the counter (OTC) drugs market; and compares it with other markets.

The report covers the following chapters

Markets Covered:

Table of Contents

1 Executive Summary

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

7 Major Market Trends

8 Over The Counter (OTC) Drugs Growth Analysis And Strategic Analysis Framework

9 Over The Counter (OTC) Drugs Market Segmentation

10 Over The Counter (OTC) Drugs Market, Regional and Country Analysis

11 Asia-Pacific Market

12 Western Europe Market

13 Eastern Europe Market

14 North America Market

15 South America Market

16 Middle East Market

17 Africa Market

18 Competitive Landscape And Company Profiles

19 Other Major And Innovative Companies

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

23 Recent Developments in Over The Counter (OTC) Drugs

24 Opportunities And Strategies

25 Over The Counter (OTC) Drugs Market, Conclusions And Recommendations

26 Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기